Turning Setbacks into Success: The Eylea Resubmission Journey

Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

Categories: Clinical Studies

Hello Regulatory Scientists,

Let’s delve into the journey of Eylea (aflibercept) from receiving an FDA Complete Response Letter (CRL) to its eventual approval. Understanding this case provides valuable insights and lessons for those developing new drugs today.

Regulatory History and Initial Submission

Drug: Eylea (aflibercept) Mechanism of Action: Vascular Endothelial Growth Factor (VEGF) inhibitor Indication: Wet age-related macular degeneration (AMD) Initial Submission Date: February 2011

The Complete Response Letter (CRL)

CRL Date: August 2011 CRL Concerns:

1. Manufacturing and Quality Control: Issues related to the consistency and quality of the manufacturing process.

2. Clinical Data: Request for additional data to confirm efficacy and safety.

3. Post-Marketing Commitments: Requirement for robust post-marketing surveillance to monitor long-term safety and effectiveness.

Resubmission Strategy

Regeneron, the company behind Eylea, implemented a meticulous strategy to address the FDA’s concerns:

1. Enhanced Manufacturing Processes: Improvements were made to the manufacturing processes to ensure consistency and quality. This involved upgrading facilities and implementing stricter quality control measures.

2. Additional Clinical Data: Conducted further clinical studies and provided additional data to confirm the drug’s efficacy and safety.

3. Post-Marketing Surveillance Plan: Developed a comprehensive post-marketing surveillance plan to monitor long-term safety and effectiveness, including detailed pharmacovigilance activities.

4. Engagement with FDA: Maintained continuous and transparent communication with the FDA to clarify requirements and align the resubmission with regulatory expectations.

Resubmission Date: September 2011

Outcome

Approval Date: November 2011 Eylea was approved for the treatment of wet AMD, marking a significant milestone in providing an effective treatment option for patients.

Lessons Learned

The journey of Eylea from CRL to approval offers several critical lessons for drug developers:

1. Proactive Quality Management: Addressing manufacturing and quality control issues proactively is crucial. Ensuring that processes meet regulatory standards can prevent delays.

2. Robust Clinical Data: Providing comprehensive and high-quality clinical data is essential to demonstrate the drug’s efficacy and safety.

3. Effective Post-Marketing Surveillance: Developing a detailed plan for post-marketing surveillance can help address long-term safety concerns and demonstrate a commitment to patient safety.

4. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations.

5. Utilizing Advisory Committees: Leveraging the expertise of advisory committees can provide valuable feedback and support the resubmission process.

Relevance for Current Drug Developers

For companies developing drugs today, the Eylea case underscores the importance of strategic planning and risk management in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval:

1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including manufacturing processes, clinical data, and post-marketing plans, meet FDA standards.

2. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review.

3. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process.

4. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns.

5. Invest in Quality Data: Prioritize the collection of high-quality data to support the submission.

The journey of Eylea from receiving a CRL to achieving FDA approval is a testament to the power of resilience, strategic planning, and meticulous execution. For companies developing drugs today, the lessons learned from Eylea’s experience underscore the importance of thorough preparation, proactive risk management, and continuous engagement with regulatory authorities.

By learning from the Eylea resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval.

Stay diligent, strategic, and proactive, and you’ll be well on your way to turning setbacks into successes.

CERES Regulatory Services.

Asad Khan

Our Blog